


# PRODUCT INFORMATION



## Lornoxicam

Item No. 70220

<b>CAS Registry No.:</b>	70374-39-9
<b>Formal Name:</b>	6-chloro-4-hydroxy-2-methyl-N-2-pyridinyl-2H-thieno[2,3-e]-1,2-thiazine-3-carboxamide-1,1-dioxide
<b>Synonyms:</b>	Chlortenoxicam, Ro 13-9297
<b>MF:</b>	C <sub>13</sub> H <sub>10</sub> ClN <sub>3</sub> O <sub>4</sub> S <sub>2</sub>
<b>FW:</b>	371.8
<b>Purity:</b>	≥98%
<b>UV/Vis.:</b>	λ <sub>max</sub> : 270, 381 nm
<b>Supplied as:</b>	A crystalline solid
<b>Storage:</b>	-20°C
<b>Stability:</b>	≥4 years



Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

### Laboratory Procedures

Lornoxicam is supplied as a crystalline solid. A stock solution may be made by dissolving the lornoxicam in the solvent of choice, which should be purged with an inert gas. Lornoxicam is soluble in the organic solvents ethanol, DMSO, and dimethyl formamide (DMF). The solubility of lornoxicam in ethanol and DMF is approximately 1 mg/ml and approximately 2 mg/ml in DMSO. It is also soluble in water at a concentration of 1 mg/ml. We do not recommend storing the aqueous solution for more than one day.

### Description

Lornoxicam is a COX inhibitor and non-steroidal anti-inflammatory drug (NSAID) with anti-inflammatory and analgesic properties.<sup>1</sup> It inhibits production of thromboxane B<sub>2</sub> (TXB<sub>2</sub>; Item No. 19030) from arachidonic acid (Item Nos. 90010 | 90010.1 | 10006607) in HEL human erythroleukemic cells (IC<sub>50</sub> = 3 nM), which endogenously express COX-1, as well as inhibits LPS-induced formation of prostaglandin F<sub>1α</sub> (PGF<sub>1α</sub>; Item No. 15010) from arachidonic acid in Mono-Mac-6 cells (IC<sub>50</sub> = 8 nM), which endogenously express COX-2. Lornoxicam reduces LPS-induced production of nitric oxide and IL-6 in cell-based assays with IC<sub>50</sub> values of 65 and 54 μM, respectively. It reduces carrageenan-induced paw edema in rats when administered intravenously at doses ranging from 0.1 to 9 mg/kg.<sup>2</sup> Formulations containing lornoxicam have been used in the management of postoperative pain.

### References

1. Berg, J., Fellier, H., Christoph, T., *et al.* The analgesic NSAID lornoxicam inhibits cyclooxygenase (COX)-1/-2, inducible nitric oxide synthase (iNOS), and the formation of interleukin (IL)-6 *in vitro*. *Inflamm. Res.* **48(7)**, 369-379 (1999).
2. Buritova, J. and Besson, J.M. Potent anti-inflammatory/analgesic effects of lornoxicam in comparison to other nsoids: A c-Fos study in the rat. *Inflammopharmacology* **5(4)**, 331-341 (1997).

#### WARNING

THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

#### SAFETY DATA

This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the complete Safety Data Sheet, which has been sent via email to your institution.

#### WARRANTY AND LIMITATION OF REMEDY

Buyer agrees to purchase the material subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website.

Copyright Cayman Chemical Company, 11/15/2022

#### CAYMAN CHEMICAL

1180 EAST ELLSWORTH RD  
ANN ARBOR, MI 48108 · USA

**PHONE:** [800] 364-9897  
[734] 971-3335

**FAX:** [734] 971-3640

CUSTSERV@CAYMANCHEM.COM  
WWW.CAYMANCHEM.COM